Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

3.87
0.0000
Volume:- -
Turnover:- -
Market Cap:26.56M
PE:-1.08
High:3.87
Open:3.87
Low:3.87
Close:3.87
52wk High:23.43
52wk Low:2.90
Shares:6.86M
Float Shares:6.46M
Volume Ratio:1.39
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5690
EPS(LYR):-7.2500
ROE:-614.05%
ROA:-135.36%
PB:4.86
PE(LYR):-0.53

Loading ...

Plus Therapeutics Inc - Cnside Diagnostics Enabled to Submit Claims for Cnside Csf Assay Platform

THOMSON REUTERS
·
May 07

Plus Therapeutics secures Blue Shield of California coverage for CNSide CSF assay

Reuters
·
Apr 28

Plus Therapeutics Secures Blue Shield of California Coverage for Cnside® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

THOMSON REUTERS
·
Apr 28

Plus Therapeutics starts REYOBIQ manufacturing technology transfer with SpectronRx under MSA

Reuters
·
Apr 23

Plus Therapeutics Initiates Manufacturing Activities With Spectronrx Under a Master Services Agreement to Support Gmp Pivotal Trial Readiness for Reyobiq™

THOMSON REUTERS
·
Apr 23

Plus Therapeutics grants new CDO inducement awards: 20,000 options, 20,000 RSUs

Reuters
·
Apr 23

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 23

Plus Therapeutics Chief Development Officer Eric Daniels files initial beneficial ownership statement

Reuters
·
Apr 22

Plus Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
Apr 21

Plus Therapeutics names Randy Goodman vice president of value strategy, HEOR

Reuters
·
Apr 15

Press Release: Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Dow Jones
·
Apr 15

Plus Therapeutics names Eric Daniels chief development officer to advance clinical pipeline

Reuters
·
Apr 09

Press Release: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Dow Jones
·
Apr 09

Plus Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $65 From $475

THOMSON REUTERS
·
Apr 09

BUZZ-Plus Therapeutics rises as FDA grants orphan drug tag for pediatric brain cancer treatment

Reuters
·
Apr 08

Plus Therapeutics wins FDA orphan drug designation for REYOBIQ in pediatric malignant gliomas

Reuters
·
Apr 08

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Reyobiq™ in Pediatric Malignant Gliomas

THOMSON REUTERS
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Terns Pharmaceuticals (TERN)

TIPRANKS
·
Apr 08

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

TIPRANKS
·
Apr 07

BUZZ- Plus Therapeutics rises as it secures new billing code for cancer test

Reuters
·
Apr 07